From Georgia State University, Vincent speaks with Chris, Andrew, Priya, and Richard about their careers and their work on Ebolaviruses, rotavirus, and antiviral drug development.

Daniel Griffin provides a clinical update on COVID-19, including analysis of the dexamethasone trial, and then we discuss two Ebolavirus outbreaks in DRC, clinical and virological aspects of asymptomatic SARS-CoV-2 infections, age-dependent effects on transmission, and answer listener email.

Vincent and Rich visit Fred Murphy to hear about his wide-ranging career in virology, spanning many institutions, involving dangerous viruses like rabies virus, Ebolavirus (he took that famous iconic image), Marburg virus, Lassa virus, coronaviruses, and later writing a history of the field.

From the Nipah Virus International Conference in Singapore, Vincent speaks with Richard Hatchett, CEO of CEPI, about its mission to stimulate and accelerate the development of vaccines against emerging infectious diseases.

The Autonomous CollecTWiVe reveal two effective treatments for Ebolavirus infection, how a virus in a fungus confers heat tolerance to a plant, and dampened inflammation as a mechanism for bat tolerance to viral infection.

Vincent travels to Microbiotix, Inc, a biopharmaceutical company in Worcester, MA to speak with four members of the company about their discovery and development of small molecule drugs that target serious infectious diseases.

Brianne and Vincent tackle two studies that utilize infectious viruses to examine zoonotic potential of Bombali virus, a new ebolavirus from an insectivorous species in Sierra Leone, and a human mumps-like virus from an African flying fox in DRC.